Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: A propensity-score matched cohort in CPRD

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 9, 2013, Pages 942-951

  Margulis, Andrea V ^a   Abou Ali, Adel ^a   Strazzeri, Marian M ^a   Ding, Yulan ^a   Kuyateh, Fatmatta ^a   Frimpong, Eric Y ^a   Levenson, Mark S ^a   Hammad, Tarek A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Congenital abnormalities; Heart defects; Mother baby link; Pharmacoepidemiology; Propensity score; SSRIS; Weighted logistic regression

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL PRACTICE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DEPRESSION; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HEART SEPTUM DEFECT; HUMAN; LIVE BIRTH; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROGENY; PROPENSITY SCORE; SECOND TRIMESTER PREGNANCY; UNITED KINGDOM;

CONGENITAL ABNORMALITIES; HEART DEFECTS; MOTHER-BABY LINK; PHARMACOEPIDEMIOLOGY; PROPENSITY SCORE; SSRIS; WEIGHTED LOGISTIC REGRESSION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; GREAT BRITAIN; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; MIDDLE AGED; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROPENSITY SCORE; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84882588716     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3462     Document Type: Article

References (51)

1. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol. Jun 2007; 196(6): 544 e1-e5. DOI: S0002-9378(07)00144-5 [pii] 10.1016/j.ajog.2007.01.033
2. Petersen I, Gilbert RE, Evans SJ, Man SL, Nazareth I. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry 2011; 72(7): 979-985. DOI: 10.4088/JCP.10m06090blu
3. DeBattista Charles, "Chapter 30. Antidepressant Agents" (Chapter). Katzung BG: Basic & Clinical Pharmacology, 2009; 11e: http://www.accessmedicine.com/content.aspx?aID=4509973.
4. Stone KJ, Viera AJ, Parman CL. Off-label applications for SSRIs. Am Fam Physician 2003; 68(3): 498-504.
5. Brown J, O' Brien PM, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2009; (2): CD001396. DOI: 10.1002/14651858.CD001396.pub2
6. MedWatch. Paroxetine HCl - Paxil and generic paroxetine. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152062.htm. Accessed May 3, 2011.
7. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007; 80(1): 18-27. DOI: 10.1002/bdrb.20099
8. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. Jun 28 2007;356(26):2684-2692. DOI: 356/26/2684 [pii] 10.1056/NEJMoa066584
9. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008; 83(1): 68-76. DOI: 10.1002/bdrb.20144
10. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356(26): 2675-2683. DOI: 356/26/2675 [pii] 10.1056/NEJMoa067407
11. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008; 66(5): 695-705. DOI: BCP3261 [pii] 10.1111/j.1365-2125.2008.03261.x
12. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009; 339: b3569. DOI: 10.1136/bmj.b3569
13. Alwan S, Friedman JM. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009; 23(6): 493-509. DOI: 10.2165/00023210-200923060-000044 [pii]
14. Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010; 88(2): 94-100. DOI: 10.1002/bdra.20641
15. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010; 2: 29-36.
16. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011; 91(3): 142-152. DOI: 10.1002/bdra.20773
17. Jimenez-Solem E, Andersen JT, Petersen M, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ open 2012; 2(3). DOI: 10.1136/bmjopen-2012-001148
18. General Practice Research Database. Available at: http://www.gprd.com/home/. Accessed October 25, 2011.
19. Charlton RA, Cunnington MC, de Vries CS, Weil JG. Data resources for investigating drug exposure during pregnancy and associated outcomes: the General Practice Research Database (GPRD) as an alternative to pregnancy registries. Drug Saf 2008; 31(1): 39-51.
20. Mother Baby Link Documentation. Medicines and Healthcare Products Regulatory Agency; GPRD Group: London, 2010.
21. Charlton RA, Weil JG, Cunnington MC, Ray S, de Vries CS. Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Saf 2011; 34(2): 157-171. DOI: 5 [pii] 10.2165/11584970-000000000-00000 [doi]
22. Cooper WO, Hickson GB, Ray WA. Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare. Paediatr Perinat Epidemiol 2004; 18(2): 106-111. DOI: 542 [pii]
23. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191(2): 398-407. DOI: 10.1016/j.ajog.2004.04.025 S000293780400420X [pii]
24. Steinkellner A, Chen W, Denison SE. Adherence to oral contraception in women on Category X medications. Am J Med 2010; 123(10): 929-934 e1. DOI: S0002-9343(10)00459-6 [pii] 10.1016/j.amjmed.2010.05.009
25. Clinical Pharmacology. Available at: http://clinicalpharmacology-ip.com/. Accessed May 19, 2011.
26. Margulis AV, Setoguchi S, Mittleman MA, Glynn RJ, Dormuth CR, Hernandez-Diaz S. Algorithms to estimate the beginning of pregnancy in administrative databases. Pharmacoepidemiology and drug safety 2 2012. DOI: 10.1002/pds.3284
27. Li Q, Andrade SE, Cooper WO, et al. Validation of an algorithm to estimate gestational age in electronic health plan databases. Pharmacoepidemiology and drug safety. Jan 21 2013. DOI: 10.1002/pds.3407
28. Ferencz C, Loffredo CA, Correa-Villaseñor A, Wilson PD. Genetic and Envionmental Risk Factors of Major Cardiovascular Malformations: The Baltimore-Washington Infant Study: 1981-1989. Vol Volume 5. Futura Publishing Company, Inc.: Armonk, New York, 1997.
29. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007; 26(4): 734-753. DOI: 10.1002/sim.2580
30. Macro %gmatch. Available at: http://mayoresearch.mayo.edu/mayo/research/biostat/sasmacros.cfm. Accessed September 15, 2011.
31. Stuart EA. Matching methods for causal inference: A review and a look forward. Stat Sci 2010; 25(1): 1-21. DOI: 10.1214/09-STS313
32. Austin PC. Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf 2008; 17(12): 1218-1225. DOI: 10.1002/pds.1674
33. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 2005; 330(7497): 960-962. DOI: 10.1136/bmj.330.7497.960
34. Hackam DG, Austin PC, Huang A, et al. Statins and Intracerebral Hemorrhage: A Retrospective Cohort Study. Arch Neurol 2011. DOI: 10.1001/archneurol.2011.228
35. Wurst KE, Ephross SA, Loehr J, Clark DW, Guess HA. Evaluation of the General Practice Research Database congenital heart defects prevalence: comparison to United Kingdom national systems. Birth defects Res Part A, Clin molecular teratology 2007; 79(4): 309-316. DOI: 10.1002/bdra.20356 [doi]
36. Rampono J, Proud S, Hackett LP, Kristensen JH, Ilett KF. A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. Int J Neuropsychopharmacol 2004; 7(3): 329-334. DOI: 10.1017/s1461145704004286
37. Kim J, Riggs KW, Misri S, et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol 2006; 61(2): 155-163. DOI: 10.1111/j.1365-2125.2005.02538.x
38. Loughhead AM, Fisher AD, Newport DJ, et al. Antidepressants in amniotic fluid: another route of fetal exposure. Am J Psychiatry 2006; 163(1): 145-147. DOI: 10.1176/appi.ajp.163.1.145
39. Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 2009; 42(3): 95-100. DOI: 10.1055/s-0028-1103296
40. Sit D, Perel JM, Wisniewski SR, Helsel JC, Luther JF, Wisner KL. Mother-infant antidepressant concentrations, maternal depression, and perinatal events. J Clin Psychiatry 2011; 72(7): 994-1001. DOI: 10.4088/JCP.10m06461
41. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269(17): 2246-2248.
42. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335(14): 1010-1015. DOI: 10.1056/NEJM199610033351402
43. Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol 2006; 22(4): 571-575. DOI: 10.1016/j.reprotox.2006.03.019
44. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther 2007; 29(5): 918-926. DOI: 10.1016/j.clinthera.2007.05.003
45. O'Brien L, Einarson TR, Sarkar M, Einarson A, Koren G. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can 2008; 30(8): 696-701.
46. Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 2010; 44(11): 978-996. DOI: 10.3109/00048674.2010.507543
47. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010; 88(3): 159-170. DOI: 10.1002/bdra.20627
48. Toh S, Mitchell AA, Werler MM, Hernandez-Diaz S. Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. Am J Epidemiol 2008; 167(6): 633-640. DOI: 10.1093/aje/kwm367
49. Palmsten K, Hernandez-Diaz S. Can nonrandomized studies on the safety of antidepressants during pregnancy convincingly beat confounding, chance, and prior beliefs? Epidemiology 2012; 23(5): 686-688. DOI: 10.1097/EDE.0b013e318258fbb2
50. Koren G. The effect of ascertainment bias in evaluating gestational antidepressant exposure. J Popul Ther Clin Pharmacol = Journal de la therapeutique des populations et de la pharamcologie clinique 2011; 18: e174-e175.
51. Palmsten K, Setoguchi S, Margulis AV, Patrick AR, Hernandez-Diaz S. Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants? Am J Epidemiol 2012; 175(10): 988-997. DOI: 10.1093/aje/kwr394